DOI: 10.1503/jpn.190179

Copyright © 2020 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.

Online appendices are unedited and posted as supplied by the authors.

Supplement Table 1. list of excluded studies with reasons for exclusion

| Excluded paper | Reason for exclusion |
|--|--------------------------------|
| Aycicegi-Dinn, 2017. TDCS and memory function among individuals with or without elevated ADHD | Conference poster |
| symptoms. Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation, 10(2), 405. | |
| Bayoumy, I. M., Khaleel, S. H., Nada, M., Awaad, M. I., Khalifa, D., & Hatata, H. (2014). Efficacy and | Could not access paper and a |
| Attributes of Repetitive Transcranial Magnetic Stimulation (rTMS) in Treatment of a Sample of Children with | translation could not be |
| Attention Deficit Hyperactivity Disorder (ADHD). Egyptian Journal of Neurology, Psychiatry & | obtained from the authors |
| Neurosurgery, 51(3). | |
| Colombo, B., Iannello, P., & Christensen, A. S. (2019). Neuromodulation as way to affect ADHD related | Conference poster |
| symptoms. A tDCS study. | |
| Krauel, K., C. Breitling, M. Dannhauer, J. Tegelbeckers, B. Bonath, H-H. Flechtner, and T. Zaehle. "Is the | Conference poster |
| right inferior frontal gyrus a promising target for tDCS in ADHD?." Brain Stimulation: Basic, Translational, | |
| and Clinical Research in Neuromodulation 10, no. 2 (2017): 530-531. | |
| Loo, C., McFarquhar, T., & Walter, G. (2006). Transcranial magnetic stimulation in adolescent | Two single-case studies in |
| depression. Australasian Psychiatry, 14(1), 81-85. | patients with Major Depression |
| | and comorbid ADHD |
| Niederhofer, H. (2008). Effectiveness of the repetitive Transcranical Magnetic Stimulation (rTMS) of 1 Hz for | Single-case study |
| Attention-Deficit Hyperactivity Disorder (ADHD). Psychiatria Danubina, 20(1), 91-92. | |
| Niederhofer, H. (2011). Additional biological therapies for attention-deficit hyperactivity disorder: repetitive | Single-case study (same as |
| transcranical magnetic stimulation of 1 Hz helps to reduce methylphenidate. Clinics and practice, 2(1), 8. | Niederhofer 2008). |
| Sarev, S., Kropotov, J. D., & Ponomarev, V. A. (2010) unpublished data in Kropotov, J. D. | Unpublished, open label |
| (2010). Quantitative EEG, event-related potentials and neurotherapy. Academic Press. | |

DOI: 10.1503/jpn.190179

Online appendices are unedited and posted as supplied by the authors.

Shugar, O., & Bronnikov, V. (2014). *Transcranial direct current stimulation in the treatment of attention* Conference poster *deficit hyperactivity disorder (ADHD) in children aged 7-12-years*. EFNS *European Journal of Neurology* 21 (Suppl. 1), 388–713

Theiner, P., Ustohal, L., Skřont, T., Bareš, M., & Kašpárek, T. (2015). Repetitive Transcranial Magnetic Single-case study Stimulation in ADHD. In *ADHD-New Directions in Diagnosis and Treatment*. InTech.

Ustohal, L., Prikryl, R., Prikrylova Kucerova, H., Sisrova, M., Stehnova, I., Venclikova, S., ... & Ceskova, E. Single case study (2012). Emotional side effects after high-frequency rTMS of the right dorsolateral prefrontal cortex in an adult patient with ADHD and comorbid depression. *Psychiatria danubina*, 24(1.), 102-103.

Zangen, A., Shahar, H., Alyagon, U., Lazarovits, A., Hadar, A., Cohen, D., ... & Tendler, A. (2016). Right Conference poster prefrontal transcranial magnetic stimulation for adults with ADHD: electrophysiological correlates and prognostic biomarkers. *Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation*, 9(5),e4.

DOI: 10.1503/jpn.190179

Online appendices are unedited and posted as supplied by the authors.

Supplement Table 2: Risk of bias ratings with supporting evidence in italics underneath.

| | Selection | on Bias | Performance Bias | Detection Bias | Attrition Bias | Reporting Bias | |
|---------------------------------|-------------------------------------|---------------------------|--|--------------------------------------|---|-------------------------------|--|
| Type of stimulation study | Random sequence generation | Allocation concealment | Blinding participants/ personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | Other bias |
| rTMS studies | | | | | | | |
| Bloch et al, | LOW | UNCLEAR single- | HIGH different | LOW | LOW | LOW | LOW |
| 2010 | randomized | blind | skin sensations | self-ratings; | none | expected outcomes | n/a |
| 2010 | | | | neurocognitive | | reported | |
| | LOW | LOW | UNCLEAR | LOW | LOW | UNCLEAR | LOW |
| Paz et al, 2017 | randomized, no | double-blind | blinding n/t | self-ratings; | none | only total scores | n/a |
| | group differences | | | neurocognitive | | reported | |
| Weaver et al, | LOW | UNCLEAR single- | UNCLEAR | LOW | LOW | LOW | LOW |
| 2012 | randomized | blind | blinding n/t | blinded raters | none | expected outcomes reported | n/a |
| tDCS studies | | | | | | | |
| A 11 1 1 | LOW | LOW | HIGH | LOW | LOW | LOW | LOW |
| Allenby et al, 2018 | randomized | double-blind | blinding failed | neurocognitive | none | expected outcomes reported | n/a |
| | LOW | UNCLEAR | UNCLEAR | LOW | LOW | HIGH | HIGH |
| Breitling et al, 2016 | randomized, no group differences | single-blind | blinding partly failed | neurocognitive | none | Flanker effect n/r | one-tailed t-tests, no multiple testing correction |
| | LOW | LOW | UNCLEAR | LOW | UNCLEAR | LOW | LOW |
| Cachoeira et al, 2017 | randomized, no group differences | double-blind | 63% guessed correctly | self-ratings | imputed data for intention-to-treat approach. | expected outcomes reported | n/a |

DOI: 10.1503/jpn.190179

Online appendices are unedited and posted as supplied by the authors.

| Cosmo et al. | LOW | LOW | UNCLEAR 43- | LOW | LOW | LOW | LOW |
|------------------------|----------------------|------------------|-----------------------------|------------------|------------------|----------------------|---------------------|
| 2015 | randomized, no | double-blind | 70% guessed | neurocognitive | none | pre-registered | n/a |
| 2015 | group differences | | correctly | | | outcomes | |
| Jaaaby at al | LOW | UNCLEAR single- | UNCLEAR | LOW | LOW | LOW | LOW |
| Jacoby et al, 2018 | probably | blind | blinding n/t | neurocognitive | none | expected outcomes | n/a |
| 2018 | randomised | | | | | reported | |
| Mana et el | LOW | LOW | LOW | LOW | LOW | LOW | LOW |
| Munz et al, | pseudo-randomized | double-blind | no side effect | neurocognitive | none | expected outcomes | n/a |
| 2015 | | | | | | reported | |
| Nejati et al, | LOW | LOW | UNCLEAR | LOW | LOW | HIGH | HIGH |
| 2017 | randomized | double-blind | blinding n/t | neurocognitive | none | Stroop effect n/r | LSD post-hoc tests |
| Prehn- | LOW | LOW | LOW | LOW | LOW ^a | LOW | LOW |
| Kristensen et | pseudo-randomized | double-blind | no side effect | neurocognitive | none | expected outcomes | n/a |
| al, 2014 | | | | | | reported | |
| Caff at al | LOW | LOW | UNCLEAR - | UNCLEAR | UNCLEAR - data | UNCLEAR | UNCLEAR |
| Soff et al, | pseudo-randomized | double-blind | 60% guessed | parent rating | post washout n/r | data post washout | |
| 2017 | no group differences | | correctly | probably blind | | n/r | |
| Soltaninejad et | LOW | UNCLEAR single- | UNCLEAR | LOW | LOW | HIGH | HIGH |
| al, 2015a | pseudo-randomized | blind | blinding n/r | neurocognitive | none | Stroop effect n/r | LSD post-hoc tests |
| Soltaninejad et | LOW | UNCLEAR single- | UNCLEAR | LOW | LOW | HIGH | LOW |
| al, 2015b ^b | pseudo-randomized | blind | blinding n/t | neurocognitive | none | Group means n/r | none |
| Sotnikova et | | | | | | HIGH | HIGH |
| | LOW ^c | LOW ^c | UNCLEAR ^c | LOW ^c | LOW ^c | | no multiple testing |
| al, 2017 | | | | | | Carryover effect n/r | correction |

^{*a*}Personal communication (30/10/18): 2 boys excluded due to technical problems on the memory task

^bInformation provided via personal communication (04/05/19)

^csame study as Soff et al, 2017

DOI: 10.1503/jpn.190179

Online appendices are unedited and posted as supplied by the authors.

| | Cor | relations | Effect Sizes | | | | erogeneity | |
|---------------|----------------------|--------------------------|--------------|-----------|-------------|---------|----------------|---------|
| Meta-analysis | Crossover Effects | Composite Effects | Study N | Hedges' g | 95% CI | p value | I ² | p value |
| Attention | 0.407 | 0.1 | 12 | 0.17 | -0.08, 0.43 | 0.19 | 77 | <0.001 |
| | 0.407 | 0.3 | 12 | 0.16 | -0.08, 0.41 | 0.20 | 69 | 0.001 |
| | 0.407 | 0.5 | 12 | 0.15 | -0.08, 0.38 | 0.21 | 61 | 0.01 |
| | 0.629 | 0.1 | 12 | 0.19 | -0.10, 0.48 | 0.19 | 81 | <0.001 |
| | 0.629 | 0.3 | 12 | 0.18 | -0.09, 0.45 | 0.20 | 75 | <0.001 |
| | 0.629 | 0.5 | 12 | 0.16 | -0.09,042 | 0.21 | 68 | 0.002 |
| | 0.780 | 0.1 | 12 | 0.22 | -0.11, 0.54 | 0.20 | 85 | <0.001 |
| | 0.780 | 0.3 | 12 | 0.20 | -0.11, 0.51 | 0.21 | 80 | <0.001 |
| | 0.780 | 0.5 | 12 | 0.18 | -0.11, 0.47 | 0.22 | 74 | <0.001 |
| Inhibition | 0.407 | 0.1 | 11 | 0.20 | 0.00, 0.41 | 0.05 | 62 | 0.01 |
| | 0.407 | 0.3 | 11 | 0.19 | 0.00, 0.38 | 0.05 | 51 | 0.03 |
| | 0.407 | 0.5 | 11 | 0.18 | -0.01, 0.36 | 0.06 | 40 | 0.06 |
| | 0.629 | 0.1 | 11 | 0.22 | 0.00, 0.45 | 0.05 | 69 | 0.002 |
| | 0.629 | 0.3 | 11 | 0.21 | -0.01, 0.43 | 0.06 | 60 | 0.01 |
| | 0.629 | 0.5 | 11 | 0.20 | -0.01, 0.40 | 0.06 | 50 | 0.02 |
| | 0.780 | 0.1 | 11 | 0.25 | -0.01, 0.51 | 0.06 | 77 | <0.001 |
| | 0.780 | 0.3 | 11 | 0.23 | -0.02, 0.48 | 0.07 | 69 | 0.002 |

Supplement Table 3: Sensitivity analyses assuming different crossover and task effect size correlations (green = significant effect)

DOI: 10.1503/jpn.190179

Online appendices are unedited and posted as supplied by the authors.

| | 0.780 | 0.5 | 11 | 0.22 | -0.02, 0.46 | 0.07 | 62 | 0.01 |
|------------------|-------|-----|----|------|-------------|------|----|------|
| Processing Speed | 0.407 | 0.1 | 8 | 0.15 | -0.01, 0.30 | 0.06 | 16 | 0.41 |
| | 0.407 | 0.3 | 8 | 0.13 | -0.02, 0.28 | 0.09 | 0 | 0.54 |
| | 0.407 | 0.5 | 8 | 0.12 | -0.04, 0.27 | 0.13 | 0 | 0.64 |
| | 0.629 | 0.1 | 8 | 0.16 | 0.00, 0.32 | 0.05 | 19 | 0.37 |
| | 0.629 | 0.3 | 8 | 0.14 | -0.01, 0.29 | 0.07 | 3 | 0.50 |
| | 0.629 | 0.5 | 8 | 0.13 | -0.02, 0.28 | 0.10 | 0 | 0.59 |
| | 0.780 | 0.1 | 8 | 0.17 | 0.01, 0.34 | 0.04 | 22 | 0.32 |
| | 0.780 | 0.3 | 8 | 0.16 | 0.00, 0.32 | 0.05 | 10 | 0.43 |
| | 0.780 | 0.5 | 8 | 0.14 | -0.01, 0.30 | 0.07 | 2 | 0.52 |

DOI: 10.1503/jpn.190179

Online appendices are unedited and posted as supplied by the authors.

| Section/topic | # | Checklist item | Reported on page # |
|---------------------------|----------|---|--------------------|
| TITLE | - | | |
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 1 |
| ABSTRACT | <u>.</u> | | |
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 2-3 |
| INTRODUCTION | ÷ | | |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 4-7 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 6-7 |
| METHODS | ÷ | | |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | n/a |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 8 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 8 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 8 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 8-9 |

DOI: 10.1503/jpn.190179

Online appendices are unedited and posted as supplied by the authors.

| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 8-10 |
|------------------------------------|----|--|-------------|
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 9-10, 50-53 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 9 |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 9-11 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis. | 10-12 |

Page 1 of 2

| Section/topic | # | Checklist item | Reported on page # | | |
|-------------------------------|----|--|-----------------------|--|--|
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 9 | | |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta- regression), if done, indicating which were pre-specified. | 11-12 | | |
| RESULTS | | | | | |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 9, 1-3 (Supplement 1) | | |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 43-49 | | |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 16, Supp Table 2 | | |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | 55 | | |

DOI: 10.1503/jpn.190179

Online appendices are unedited and posted as supplied by the authors.

| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | 18-20, 55, 67-69 |
|-----------------------------|----|--|---------------------------|
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | 32, 4-7 (Supplement 1) |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta- regression [see Item 16]). | 61-63, 8-9 (Supplement 1) |
| DISCUSSION | | | |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 18-25 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 22-24 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 24-25 |
| FUNDING | - | | |
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | 26 |

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2